NCT01170572

Brief Summary

Studies in chickens show that blood levels of a particular form of vitamin D (called 24,25-dihydroxvitamin D) increase after bone fracture. Laboratory studies show that this form of vitamin D helps the bone healing process in chickens. The investigators want to find out whether blood levels of this form of vitamin D increase after bone fracture in humans. Previous research studies have not addressed this question. The results of this research could eventually lead to the development of new treatments to help bone healing after fracture. Patients will be asked to take part in this study if they are aged 16 years or older and come to the Royal London Hospital with a broken bone in the arm or leg or collar bone (clavicle). They will be asked to give a 20ml (about 4 teaspoons) blood sample on three occasions: at the start of the study, at 5-14 days after the fracture; and at 4-10 weeks after the fracture. The rest of their normal care would not be affected. Follow-up blood samples will be timed to coincide with routine clinic visits which are scheduled as part of normal clinical care. Patients' vitamin D level will be measured as part of the study, and those who have a low vitamin D level will be informed about this, and advised about appropriate vitamin D supplementation. The investigators will let the patient or their GP know if any blood tests are abnormal

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2010

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 26, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 27, 2010

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2010

Completed
Last Updated

November 7, 2012

Status Verified

November 1, 2012

Enrollment Period

7 months

First QC Date

July 26, 2010

Last Update Submit

November 6, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Serum concentration of 24,25-dihyroxyvitamin D at 5-14 days post cross sectional long bone or clavicle fracture, compared with baseline.

    5-14 days post fracture

Secondary Outcomes (2)

  • Serum concentrations of vitamin D metabolites (including 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D) and markers of bone healing

    Baseline, 5-14 days, and 4-10 weeks post fracture

  • Peripheral blood expression of genes encoding enzymes in the vitamin D metabolic pathway.

    Baseline, 5-14 days, and 4-10 weeks post fracture

Study Arms (1)

Long bone fracture

Patients presenting to accident and emergency during the study period with long bone or clavicle fracture

Other: No intervention

Interventions

No intervention

Long bone fracture

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients presenting to the Accident and Emergency Department, Royal London Hospital, Whitechapel with a long bone or clavicle fracture

You may qualify if:

  • Any cross-shaft long bone or clavicle fracture within last 12 hours
  • Able to give written informed consent
  • Age ≥ 16 years
  • Fused physes (physiologically adult)

You may not qualify if:

  • Taking medication affecting vitamin D metabolism - carbamazepine, phenobarbital, phenytoin or primidone
  • Taking vitamin D supplement \> 800 IU/day
  • Abdominal visceral injury, pleural injury (except pneumothorax), spinal cord injury, or GCS \< 15 at presentation to hospital
  • Known Paget's disease, osteopetrosis, metastatic bone cancer, or primary bone cancer
  • Current prisoners
  • Currently taking part in another clinical research project

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Royal London Hospital

London, London, E1 1BB, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood samples will be retained

Study Officials

  • Adrian Martineau, MRCP

    Queen Mary University of London

    STUDY DIRECTOR
  • Tim Harris, BM BS

    Barts and the London NHS Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 26, 2010

First Posted

July 27, 2010

Study Start

March 1, 2010

Primary Completion

October 1, 2010

Study Completion

October 1, 2010

Last Updated

November 7, 2012

Record last verified: 2012-11

Locations